Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HLA class I histocompatibility antigen, alpha chain G (HLA-G) is a nonclassical major histocompatibility complex class Ib molecule encoded by the HLA-G gene, functioning primarily in immune regulation at the maternal-fetal interface to promote tolerance by inhibiting NK cells, T cells, B cells, and other immune effectors through interactions with receptors like ILT2, ILT4, LILRB1, LILRB2, and KIR2DL4; it forms a heterodimer with beta-2 microglobulin, presents a restricted repertoire of self-peptides (e.g., from histones), and exists in multiple membrane-bound (HLA-G1 to G4) and soluble isoforms (HLA-G5 to G7) generated by alternative splicing, with expression limited to sites like placenta, trophoblasts, and tumors
CAR T-cell targeting as immune checkpoint and tumor-specific antigen
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HLA class I histocompatibility antigen, alpha chain G (HLA-G) (HLA-G).